Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Medical Affairs Reputations: CLL (US) 2017

Product Code:
596200914
Publication Date:
September 2017
Format:
PPTX
Price:
€5925

How well does your CLL medical affairs team performance compare with the rest?

Is ‘moderately satisfied’ good enough? According to this latest survey of 100 US medical oncologists and haematologists, the performance of chronic lymphocytic leukaemia medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board.  Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. 

Use Medical Affairs Reputations: Chronic Lymphocytic Leukaemia 2017 (US) to discover how your team can better meet the high expectations of physicians at the frontline. 

This report compares the current activities of medical affairs teams for the six leading CLL treatments from Novartis, Gilead, Roche, Janssen Biotech, AbbVie and Biogen. It shows:

  • How physicians rate each team overall, and for 12 key medical affairs services.
  • What is most important to physicians, plus what can be done better.
  • How, and how often physicians want to meet with your team.

It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage. 

Interested in the European market? Click here to see the EU5 Edition.

Request sample pages

Top Takeaways

  • Stand out or forgettable? One team strides ahead with 85% of physicians recalling an interaction within the last 6 months – whereas another is lagging way behind with a half-hearted response. How does your team stack up?
  • Patient focus: How much do US physicians rely on medical affairs to help them improve patient access, education and outcomes? And are they spending more or less time doing this than before?
  • Not so dynamic duo: Two teams top the satisfaction table for many (but not all) medical affairs attributes. Where are their weak spots and who is maximising on them? 
  • Shared goal: Physicians identified the same important opportunity for improvement for 3 out of 6 medical affairs teams. Just what should all of them be focusing on right now? 
  • Good news for all: Physicians praised every drug for at least 4 areas of support provided by medical affairs teams. 
  • Consider the 80:20 rule: 1 in 5 survey respondents suggest more can be done to provide specific information, and that attitudes could be improved. Could addressing these tip the balance? 

Insight into Medical affairs teams for these CLL treatments

  • Arzerra (ofatumumab; Novartis)
  • Gazyva (obinutuzumab; Roche)
  • Imbruvica (ibrutinib; Janssen Biotech/AbbVie)
  • Rituxan (rituximab; Roche/Biogen)
  • Venclexta (venetoclax; Roche/AbbVie)
  • Zydelig (idelalisib; Gilead)

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 6 medical affairs teams—answering important questions like:

What do physicians need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team’s interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition—in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 100 US-based medical oncologists and haematologists—chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 CLL patients a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product’s medical affairs team in the past 6 months.

We conducted the survey between August 1st and August 16th, 2017.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved